COST Action 'ImpARAS': what have we learnt to improve food allergy risk assessment. A summary of a 4 year networking consortium.

Allergy risk assessment Decision-making criteria Food allergy de novo sensitisation

Journal

Clinical and translational allergy
ISSN: 2045-7022
Titre abrégé: Clin Transl Allergy
Pays: England
ID NLM: 101576043

Informations de publication

Date de publication:
2020
Historique:
received: 13 03 2020
accepted: 27 04 2020
entrez: 2 6 2020
pubmed: 2 6 2020
medline: 2 6 2020
Statut: epublish

Résumé

The growing world population and increased pressure on agricultural resources are driving a shortage of dietary protein sources. As a result, industry is developing more sustainable novel food protein sources such as insects, algae and duckweed and using new processing techniques. Consumer exposure to these novel or processed proteins, could cause new food allergies, exacerbating a public health issue which is already directly affecting an estimated 20 million Europeans. Introduction of novel foods should not add to the burden of food allergy and this calls for a reliable, harmonised, evidence-based and validated allergenicity risk assessment strategy. The COST (Cooperation in Science and Technology) Action ImpARAS (Improved Allergenicity Risk Assessment Strategy), a four-year networking project, identified gaps in current allergy risk assessment, and proposed new ideas and plans for improving it. Here, we report on the lessons learned from the ImpARAS network and suggestions for future research. The safe introduction of novel and more sustainable food protein sources, while protecting humans from food allergy, calls for a multidisciplinary approach based on an improved understanding of what determines the relative allergenic potency of proteins, novel testing and assessment methodologies, harmonized decision-making criteria, and a clear ranking approach to express the allergenicity of novel product relative to that of existing known allergenic proteins: (from 'non'/to weakly and to strongly allergenic proteins).

Identifiants

pubmed: 32477491
doi: 10.1186/s13601-020-00318-x
pii: 318
pmc: PMC7236523
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

13

Informations de copyright

© The Author(s) 2020.

Déclaration de conflit d'intérêts

Competing interestsThe authors declare that they have no competing interests in this section.

Références

J Allergy Clin Immunol. 2018 Jan;141(1):41-58
pubmed: 29157945
J Allergy Clin Immunol. 2017 Aug;140(2):600-603.e7
pubmed: 28274747
Mol Nutr Food Res. 2018 Jan;62(1):
pubmed: 28925060
Clin Transl Allergy. 2016 Jun 16;6:21
pubmed: 27313841
Regul Toxicol Pharmacol. 2016 Aug;79:118-124
pubmed: 27012375
Allergy. 2012 Aug;67(8):1023-32
pubmed: 22737987
Toxicol Lett. 2016 Nov 16;262:62-69
pubmed: 27663974

Auteurs

Kitty Verhoeckx (K)

1TNO, Utrechtseweg 48, Zeist, The Netherlands.

Katrine Lindholm Bøgh (K)

2National Food Institute, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark.

Anne Constable (A)

Nestlé Research, Lausanne, Switzerland.

Michelle M Epstein (MM)

4Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, Room 4P9.02, 1090 Vienna, Austria.

Karin Hoffmann Sommergruber (K)

5Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.

Thomas Holzhauser (T)

6Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany.

Geert Houben (G)

1TNO, Utrechtseweg 48, Zeist, The Netherlands.

Annette Kuehn (A)

7Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sûr-Alzette, Luxemburg.

Erwin Roggen (E)

3Rs Management and Consulting ApS, Asavænget 14, Lyngby, Denmark.

Liam O'Mahony (L)

9Department of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland.

Ben Remington (B)

1TNO, Utrechtseweg 48, Zeist, The Netherlands.

René Crevel (R)

René Crevel Consulting Ltd, Bedford, UK.

Classifications MeSH